What is it about?
Pancreatic cancer is the cancer with highest mortality-incidence rate compared with other types of cancer. Most cases can only be treated palliatively. Targeted therapy comes as an alternative to its treatment especially with Switchable CAR T-cells (sCAR T-cells). In pancreatic cancer, urokinase plasminogen activator receptor (uPAR) is a specific target that is excessively expressed in tumor cell microenvironment. Targeted therapy using sCAR T-cells has been proved safe and effective in other types of malignancy such as B cell lymphoma, so it has potency as immunotherapy agent in pancreatic cancer patient.
Featured Image
Why is it important?
uPAR targeted therapy with sCAR T-cell is potential to be used in pancreatic cancer treatment. uPAR is the most specific pancreatic cancer biomarker, meanwhile sCAR T-cell use facilitating graded titration and better T cell regulation which is used to prevent adverse outcome of pancreatic cancer treatment, including Cytokine Release Syndrome.
Perspectives
Future research is needed to determine most functional parts of VIM5 antibody fragment that can be inserted to PNE that can optimizing sCAR T cell work. Effect analysis, dose, and side effects must be assessed in next research for maintaining uPAR targeted therapy with sCAR T-Cell effectiveness and safety.
Dr. Tungki Pratama Umar
Universitas Sriwijaya
Read the Original
This page is a summary of: Urokinase Plasminogen Activator Receptor (uPAR) Targeted Therapy with Switchable Chimeric Antigen Receptor T-Cell (sCAR T-Cell) Potential as Pancreatic Cancer Immunotherapy Agent, International Journal of Human and Health Sciences (IJHHS), October 2020, International Journal of Human and Health Sciences IJHHS,
DOI: 10.31344/ijhhs.v5i2.255.
You can read the full text:
Contributors
The following have contributed to this page
